Pro-Dex

PDEX · NASDAQ

$59.40+$1.70 (+2.94%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $57.70

PDEX analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $75.48 (+27.1% upside)

Low: $74.74
Now: $59.40
High: $77.70

Upgrades and downgrades

The latest rating actions, newest first

PDEX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Sep 11, 2026	Maintains	Buy	$70.00 → $74.00	28%
Ascendiant Capital	May 12, 2026	Maintains	Buy	$56.00 → $70.00	28%

The case for and against

Updated Oct 18, 2026

Bull case

Pro-Dex is supported by accelerating demand for its specialized medical devices, with fiscal Q4 2026 revenue up 17% to $20.4 million and EPS of $0.86, both ahead of expectations, while gross margin expanded to 35% from 20% on better mix and operating leverage. The company’s long record of growth, including FY25 revenue up 24% and FY26 up 16%, reflects successful new product wins and private-label investment, and its FY27 revenue and EPS estimates have been raised to $83 million and $3.09. Its February 2026 acquisition of Advanced Precision Machining for $8.7 million should broaden customer and product diversification, add aerospace and defense exposure, and improve manufacturing scale and efficiency.

Bear case

Pro-Dex is facing a fundamentally fragile operating backdrop because its results depend on shifting demand for technology, investor sentiment toward technology stocks, competition, and broader macroeconomic conditions, all of which can pressure valuation and execution. Revenue grew 15% year over year, but that improvement was driven by new medical device product revenue rather than broad-based strength, while lower repairs revenue suggests an uneven mix and less durable demand. Gross margin also declined to 31% from 33% year over year, indicating unfavorable product mix and weaker profitability quality despite the top-line increase.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.